CLINICAL_TRIALS
trial_result
· 2016-02-08
Clinical Trial Update: CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib [Phase 4]
Summary
Phase 4 trial update reports the rate of complete molecular response (CMR) in newly diagnosed chronic myeloid leukemia patients treated with nilotinib.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia in Chronic Phase | Phase 4 | Status: COMPLETED | Results posted: 2016-02-08